Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modern plasma fractionation.

Thierry Burnouf1

  • 1Human Plasma Product Services, Lille, France. tburnou@attglobal.net

Transfusion Medicine Reviews
|April 3, 2007
PubMed
Summary
This summary is machine-generated.

Modern plasma fractionation ensures safe therapeutic protein products through advanced manufacturing and viral inactivation. These essential treatments, derived from pooled human plasma, are among the safest biological products available today.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A microfluidic platform for isolating functional mitochondria and restoring bioenergetic activity in hypoxia-injured cardiomyocytes.

International journal of biological macromolecules·2026
Same author

Essential but neglected: securing the global supply of human hyperimmune immunoglobulins.

The Lancet. Haematology·2026
Same author

Platelet membrane-coated nanoparticles: Bioengineering principles, quality control, and translational opportunities.

APL bioengineering·2026
Same author

Immune dysregulation in mania: A proof-of-concept platelet proteomics study.

Psychiatry and clinical neurosciences·2026
Same author

Platelet-derived and platelet secretome biotherapies for precision neuromedicine.

Trends in molecular medicine·2026
Same author

An Exploratory Study of Kinase Activation Profiles in Hypoxic Human Cardiomyocytes Treated with Protective Extracellular Vesicles.

Research square·2026

Area of Science:

  • Biotechnology
  • Biopharmaceutical Manufacturing
  • Plasma Protein Therapeutics

Background:

  • Plasma-derived protein therapeutics are vital for treating life-threatening conditions.
  • Traditional ethanol fractionation is the basis of modern plasma product manufacturing.
  • Advancements have improved purity, immunoglobulin G recovery, and isolation of new proteins.

Purpose of the Study:

  • To review modern plasma fractionation industry practices.
  • To detail quality requirements and viral inactivation/removal treatments.
  • To highlight manufacturing and regulatory aspects of plasma protein therapies.

Main Methods:

  • Review of plasma collection, fractionation, and purification processes.
  • Description of viral inactivation and removal techniques.

Related Experiment Videos

  • Analysis of Good Manufacturing Practices (GMP) and regulatory frameworks.

    • Main Results:

    • Modern plasma fractionation employs extensive safety measures, including dedicated viral inactivation and removal steps.
    • These processes significantly mitigate the risk of transmitting blood-borne infectious agents (e.g., HIV, HBV, HCV).
    • Fractionated plasma products manufactured under current standards are considered low-risk therapeutic biological products.

    Conclusions:

    • Modern plasma fractionation processes, combined with stringent safety protocols, yield highly purified and safe protein therapeutics.
    • Continuous improvements in technology and regulation ensure the safety and efficacy of plasma-derived medicines.
    • Plasma protein therapies produced through contemporary methods represent a safe and essential component of modern medicine.